RPRXライブシグナル | Getagraph.comで利益を最大化

売る 124 min ago

@ $28.15

発行日: 29 4月 2024 @ 23:40

リターン: -0.50%

前回のシグナル: 4月 27 - 02:00

前回のシグナル: 買う

リターン: 0.25 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:44):

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States...

Stats
本日の出来高	1.30M
平均出来高	2.81M
時価総額	12.51B
EPS	$0 ( 2024-02-15 )
次の収益日	( $0.960 ) 2024-05-09
Last Dividend	$0.200 ( 2023-11-16 )
Next Dividend	$0 ( N/A )
P/E	11.07
ATR14	$0.240 (0.86%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Fernandez Henry A	Buy	1 240	Class A Ordinary Shares
2024-03-28	Bassler Bonnie L	Buy	1 240	Class A Ordinary Shares
2024-02-20	Riggs Rory B	Buy	300 000	Class A Ordinary Shares
2024-02-20	Riggs Rory B	Sell	30 000	LP interests in RPI US Partners 2019, LP
2024-01-02	Riggs Rory B	Sell	235 200	Class A Ordinary Shares

INSIDER POWER
-36.03
Last 100 transactions
Buy: 3 308 362 \| Sell: 7 318 226

ボリューム相関

長: -0.20 (neutral)

短: 0.39 (neutral)

Signal:(50) Neutral

Royalty Pharma plc 相関

10 最も正の相関
INCR	0.957
MYSZ	0.939
SPFI	0.937
BMRA	0.933
WATT	0.931
CUTR	0.93
CSSEP	0.925
BWB	0.919
EVLO	0.918
TIVC	0.918

10 最も負の相関
ESCA	-0.946
AMTBB	-0.945
BRLI	-0.945
GRIL	-0.944
ARIZ	-0.941
CNGL	-0.94
GBRG	-0.936
EMLD	-0.934
LQDA	-0.934
GANX	-0.931

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Royalty Pharma plc 相関 - 通貨/商品

0.37
( neutral )

0.03
( neutral )

0.00
( neutral )

0.09
( neutral )

0.21
( neutral )

-0.29
( neutral )

Royalty Pharma plc 財務諸表

Annual	2023
収益:	$2.35B
総利益:	$1.79B (76.19 %)
EPS:	$2.54

FY	2023
収益:	$2.35B
総利益:	$1.79B (76.19 %)
EPS:	$2.54

FY	2022
収益:	$2.24B
総利益:	$2.23B (99.75 %)
EPS:	$0.0978

FY	2021
収益:	$2.29B
総利益:	$0.00 (0.00 %)
EPS:	$0.922

Financial Reports:

No articles found.

Royalty Pharma plc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.190 (N/A)	$0.190 (N/A)	$0.200 (N/A)	$0.200 (N/A)	$0.200 (N/A)	$0.200 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Royalty Pharma plc Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 7.90 - Increase likely (57.98%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.150	2020-09-14
Last Dividend	$0.200	2023-11-16
Next Dividend	$0	N/A
Payout Date	2023-12-15
Next Payout Date	N/A
# dividends	14	--
Total Paid Out	$2.54	--
Avg. Dividend % Per Year	1.17%	--
Score	4.94	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	7.90
Div. Directional Score	9.45	--

Next Divdend (Est)
(2024-07-01)

$0.205 Estimate 38.46 %

Dividend Stability

0.77 Good

Dividend Score

4.94

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2020	$0.300	0.67%
2021	$0.680	1.45%
2022	$0.760	1.93%
2023	$0.800	2.03%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.482	1.500	0.360	0.540	[0 - 0.5]
returnOnAssetsTTM	0.0693	1.200	7.69	9.23	[0 - 0.3]
returnOnEquityTTM	0.182	1.500	9.09	10.00	[0.1 - 1]
payoutRatioTTM	0.316	-1.000	6.84	-6.84	[0 - 1]
currentRatioTTM	7.90	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	7.87	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.96	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.375	-1.500	3.76	-5.64	[0 - 0.6]
interestCoverageTTM	7.98	1.000	8.15	8.15	[3 - 30]
operatingCashFlowPerShareTTM	6.70	2.00	7.77	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.964	2.00	9.02	10.00	[0 - 20]
debtEquityRatioTTM	0.940	-1.500	6.24	-9.36	[0 - 2.5]
grossProfitMarginTTM	0.697	1.000	1.719	1.719	[0.2 - 0.8]
operatingProfitMarginTTM	0.634	1.000	10.00	10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.488	1.000	8.40	8.40	[0.2 - 2]
assetTurnoverTTM	0.144	0.800	-2.38	-1.900	[0.5 - 2]
Total Score				11.00

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	11.02	1.000	8.99	0	[1 - 100]
returnOnEquityTTM	0.182	2.50	9.41	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.964	2.00	9.35	10.00	[0 - 30]
dividendYielPercentageTTM	2.89	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.70	2.00	7.77	10.00	[0 - 30]
payoutRatioTTM	0.316	1.500	6.84	-6.84	[0 - 1]
pegRatioTTM	0.802	1.500	7.99	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	1.271	1.000	10.00	0	[0.1 - 0.5]
Total Score				7.90

Royalty Pharma plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.